116 related articles for article (PubMed ID: 38354922)
1. TMED2 promotes glioma tumorigenesis by being involved in EGFR recycling transport.
Sun C; Zhang Y; Wang Z; Chen J; Zhang J; Gu Y
Int J Biol Macromol; 2024 Mar; 262(Pt 2):130055. PubMed ID: 38354922
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
Suina K; Tsuchihashi K; Yamasaki J; Kamenori S; Shintani S; Hirata Y; Okazaki S; Sampetrean O; Baba E; Akashi K; Mitsuishi Y; Takahashi F; Takahashi K; Saya H; Nagano O
Cancer Sci; 2018 Dec; 109(12):3874-3882. PubMed ID: 30298963
[TBL] [Abstract][Full Text] [Related]
3. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
Oh H; Hwang I; Jang JY; Wu L; Cao D; Yao J; Ying H; Li JY; Yao Y; Hu B; Wang Q; Zheng H; Paik J
Cancer Res; 2021 Mar; 81(6):1528-1539. PubMed ID: 33509942
[TBL] [Abstract][Full Text] [Related]
4. MiR-3918 Inhibits Tumorigenesis of Glioma via Targeting EGFR to Regulate PI3K/AKT and ERK Pathways.
Han Y; Wang H
J Mol Neurosci; 2022 Feb; 72(2):433-440. PubMed ID: 35023001
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic DIRAS3 promotes malignant phenotypes of glioma by activating EGFR-AKT signaling.
Peng Y; Jia J; Jiang Z; Huang D; Jiang Y; Li Y
Biochem Biophys Res Commun; 2018 Oct; 505(2):413-418. PubMed ID: 30266404
[TBL] [Abstract][Full Text] [Related]
6. Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor.
Zhou X; Xie S; Wu S; Qi Y; Wang Z; Zhang H; Lu D; Wang X; Dong Y; Liu G; Yang D; Shi Q; Bian W; Yu R
Neuro Oncol; 2017 Nov; 19(12):1628-1639. PubMed ID: 28575494
[TBL] [Abstract][Full Text] [Related]
7. TMED2 Potentiates Cellular IFN Responses to DNA Viruses by Reinforcing MITA Dimerization and Facilitating Its Trafficking.
Sun MS; Zhang J; Jiang LQ; Pan YX; Tan JY; Yu F; Guo L; Yin L; Shen C; Shu HB; Liu Y
Cell Rep; 2018 Dec; 25(11):3086-3098.e3. PubMed ID: 30540941
[TBL] [Abstract][Full Text] [Related]
8. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
9. TMED2/emp24 is required in both the chorion and the allantois for placental labyrinth layer development.
Hou W; Jerome-Majewska LA
Dev Biol; 2018 Dec; 444(1):20-32. PubMed ID: 30236446
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease in mice with heterozygous mutation in TMED2.
Hou W; Gupta S; Beauchamp MC; Yuan L; Jerome-Majewska LA
PLoS One; 2017; 12(8):e0182995. PubMed ID: 28797121
[TBL] [Abstract][Full Text] [Related]
11. IGFBP2 potentiates nuclear EGFR-STAT3 signaling.
Chua CY; Liu Y; Granberg KJ; Hu L; Haapasalo H; Annala MJ; Cogdell DE; Verploegen M; Moore LM; Fuller GN; Nykter M; Cavenee WK; Zhang W
Oncogene; 2016 Feb; 35(6):738-47. PubMed ID: 25893308
[TBL] [Abstract][Full Text] [Related]
12. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.
Yiin JJ; Hu B; Schornack PA; Sengar RS; Liu KW; Feng H; Lieberman FS; Chiou SH; Sarkaria JN; Wiener EC; Ma HI; Cheng SY
Mol Cancer Ther; 2010 Apr; 9(4):929-41. PubMed ID: 20371720
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA BCAR4 promotes glioma cell proliferation via EGFR/PI3K/AKT signaling pathway.
Wei L; Yi Z; Guo K; Long X
J Cell Physiol; 2019 Dec; 234(12):23608-23617. PubMed ID: 31173355
[TBL] [Abstract][Full Text] [Related]
14. A network pharmacology- and transcriptomics-based investigation reveals an inhibitory role of β-sitosterol in glioma via the EGFR/MAPK signaling pathway.
Xie Y; Chen Z; Li S; Yan M; He W; Li L; Si J; Wang Y; Li X; Ma K
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):223-238. PubMed ID: 38143380
[TBL] [Abstract][Full Text] [Related]
15. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180.
Feng H; Hu B; Vuori K; Sarkaria JN; Furnari FB; Cavenee WK; Cheng SY
Oncogene; 2014 May; 33(19):2504-12. PubMed ID: 23728337
[TBL] [Abstract][Full Text] [Related]
16. Mucin O-glycosylating enzyme GALNT2 facilitates the malignant character of glioma by activating the EGFR/PI3K/Akt/mTOR axis.
Sun Z; Xue H; Wei Y; Wang C; Yu R; Wang C; Wang S; Xu J; Qian M; Meng Q; Li G
Clin Sci (Lond); 2019 May; 133(10):1167-1184. PubMed ID: 31076460
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop.
Zhang X; Niu W; Mu M; Hu S; Niu C
J Exp Clin Cancer Res; 2020 Sep; 39(1):196. PubMed ID: 32962742
[TBL] [Abstract][Full Text] [Related]
19. [The anti-cancer effect of ZR30 protein via targeting extracellular signal proteins of different cell subpopulations of glioma].
Li YY; Chen XH; Sun T; Hu Y; Zhou YH; Zhou YX
Zhonghua Zhong Liu Za Zhi; 2018 Nov; 40(11):812-817. PubMed ID: 30481930
[No Abstract] [Full Text] [Related]
20. EGFR signals to mTOR through PKC and independently of Akt in glioma.
Fan QW; Cheng C; Knight ZA; Haas-Kogan D; Stokoe D; James CD; McCormick F; Shokat KM; Weiss WA
Sci Signal; 2009 Jan; 2(55):ra4. PubMed ID: 19176518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
